Effects of fibrates in kidney disease: a systematic review and meta-analysis.

[1]  T. Gomes,et al.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. , 2012 .

[2]  A. Garg,et al.  New Fibrate Use and Acute Renal Outcomes in Elderly Adults , 2012, Annals of Internal Medicine.

[3]  T. Craven,et al.  Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants , 2012, Diabetes Care.

[4]  A. Keech,et al.  Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment , 2012, Diabetes Care.

[5]  P. McCullough,et al.  Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events. , 2011, Reviews in cardiovascular medicine.

[6]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[7]  陳玉玲.  Fenofibrate Reversibly Increases Serum Creatinine Level in Chronic Kidney Disease Patients by Reducing Glomerular Filtration Rate , 2011 .

[8]  D. Andreini,et al.  Complementary role of cardiac computed tomography and Doppler-echocardiography in the evaluation of an uncommon case of giant pseudoaneurysm of ascending aorta complicated by fistula to the pulmonary artery. , 2011, Journal of cardiovascular medicine.

[9]  V. Gebski,et al.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study , 2011, Diabetologia.

[10]  J. Danesh,et al.  Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study , 2010, BMJ : British Medical Journal.

[11]  A. Zanchetti,et al.  Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. , 2010, Journal of the American College of Cardiology.

[12]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[13]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[14]  R. Atkins,et al.  Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  H. Abboud,et al.  Clinical practice. Stage IV chronic kidney disease. , 2010, The New England journal of medicine.

[16]  A. Keech,et al.  Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study , 2010, Diabetologia.

[17]  M. Tonelli,et al.  Cardiovascular risk and management in chronic kidney disease , 2009, Nature Reviews Nephrology.

[18]  M. Woodward,et al.  Lowering blood pressure reduces renal events in type 2 diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[19]  J. Ansquer,et al.  Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  W. Brown,et al.  Expert commentary: the safety of fibrates in lipid-lowering therapy. , 2007, The American journal of cardiology.

[21]  A. Garg,et al.  Chronic kidney disease and mortality risk: a systematic review. , 2006, Journal of the American Society of Nephrology : JASN.

[22]  N. Vaziri.  Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. , 2006, American journal of physiology. Renal physiology.

[23]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[24]  M. Taskinen,et al.  Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  H. Bloomfield,et al.  Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  H. Bloomfield,et al.  Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. , 2004, Kidney international.

[27]  Daniel Levy,et al.  Predictors of new-onset kidney disease in a community-based population. , 2004, JAMA.

[28]  J. Buring,et al.  Cholesterol and the risk of renal dysfunction in apparently healthy men. , 2003, Journal of the American Society of Nephrology : JASN.

[29]  David W Dunstan,et al.  Prevalence of kidney damage in Australian adults: The AusDiab kidney study. , 2003, Journal of the American Society of Nephrology : JASN.

[30]  B. Kasiske,et al.  K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease , 2003 .

[31]  G. Eknoyan,et al.  On the evolving nature of understanding dialysis-related disorders. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  B. Kasiske,et al.  K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease , 2003 .

[34]  K. Iseki,et al.  Influence of smoking and obesity on the development of proteinuria. , 2002, Kidney international.

[35]  J. Achard,et al.  Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine , 2002, Nephron.

[36]  Peter Jüni,et al.  Quality of reporting of randomized trials as a measure of methodologic quality. , 2002, JAMA.

[37]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  Kenneth F Schulz,et al.  Blinding in randomised trials: hiding who got what , 2002, The Lancet.

[40]  K Doqi,et al.  clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification , 2002 .

[41]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[43]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[44]  O. Devuyst,et al.  Deterioration in renal function associated with fibrate therapy. , 2001, Clinical nephrology.

[45]  D. Abramowicz,et al.  Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  J. Coresh,et al.  Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. , 2000, Kidney international.

[47]  R. Shapiro,et al.  A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. , 2000, Clinical nephrology.

[48]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[49]  C. Wanner,et al.  Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[50]  J. Achard,et al.  [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. , 1999, Nephrologie.

[51]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[52]  H. Mulec,et al.  Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. , 1997, Nephron.

[53]  T. Cundy,et al.  Renal function changes in diabetic nephropathy induced by bezafibrate. , 1996, Nephron.

[54]  V. Manninen,et al.  Effects of hypertension and dyslipidemia on the decline in renal function. , 1995, Hypertension.

[55]  O. Devuyst,et al.  Creatinine rise after fibrate therapy in renal graft recipients , 1993, The Lancet.

[56]  M. Yacoub,et al.  Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients. , 1992, The American journal of cardiology.

[57]  Louette R. Johnson Lutjens.  Research , 2006 .